The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis

Thrombosis and Haemostasis

Volumn 99, Issue 5, 2008, Pages 925-929

  Rehak, Matus ^a,b   Rehak, Jiri ^b   Müller, Marc ^a   Faude, Susanne ^a   Faude, Frank ^a   Siegemund, Annelie ^a   Krcova, Vera ^b   Slavik, Ludek ^b   Hasenclever, Dirk ^c   Scholz, Markus ^c   Wiedemann, Peter ^a,c  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Activated protein C; APC resistance; Factor V Leiden; Meta analysis; Retinal vein occlusion

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; RISK FACTOR; THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CZECH REPUBLIC; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GERMANY; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; RETINAL VEIN OCCLUSION; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM;

EID: 43949127059     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-11-0658     Document Type: Article

References (31)

1. The Eye Disease Case-Control Study Group: Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114: 545-554.
2. Weger M, Renner W, Steinbrugger I, et al. Role of thrombophilic gene polymorphisms in branch retinal vein occlusion. Ophthalmology 2005; 112: 1910-1915.
3. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003; 136: 1136-1150.
4. Janssen MC, de Heijer M, Cruysberg JR, et al. Retinal vein occlsuion: a form of venous thrombosis or a complication of atherosclerosis? Thromb Haemost 2005; 93: 1021-1026.
5. Leoncini G, Bruzzese D, Signorello MG, et al. Platelet activation by collagen is increased in retinal vein occlusion. Thromb Haemost. 2007; 97: 218-227.
6. Fateh-Moghadam S, Gawaz M. Retinal vein occlusion disease and platelet activation: will antiplatelet therapy be a promising therapeutic strategy for patients with retinal vein occlusion disease in the future? Thromb Haemost 2007; 97: 169-170.
7. Lippi G, Franchini M, Targher G. Platelets and lipoprotein(a) in retinal vein occlusion: mutual targets for aspirin therapy. Thromb Haemost 2007; 97: 1059-1060.
8. Gumus K, Kadayifcilar S, Eldem B, et al. Is elevated level of soluble endothelial protein C receptor a new risk factor for retinal vein occlusion? Clin Experiment Ophthalmol 2006; 34: 305-311.
9. Arsene S, Delahousse B, Regina S, et al. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 2005: 94: 101-106.
10. Albisinni R, Coppola A, Loffredo M, et al. Retinal vein occlusion and inherited conditions predisposing to thrombophilia. Thromb Haemost 1998; 80: 702-703.
11. Marcucci R, Bertini L, Giusti B, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86: 772-776.
12. Larsson J, Hillarp A, Olafsdottir E, et al. Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmol Scand 1999; 77: 634-637.
13. Greiner K, Peetz D, Winkgen A, et al. Genetic thrombophilia in patients with retinal vascular occlusion. Int Ophthalmol. 1999; 23: 155-160.
14. Gottlieb JL, Blice JP, Mestichelli B, et al. Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol 1998; 116: 577-579.
15. Demirci FY, Güney DB, Akarcay K, et al. Prevalence of factor V Leiden in patients with retinal vein occlusion. Acta Ophthalmol Scand 1999; 77: 631-633.
16. Cruciani F, Moramarco A, Curto T, et al. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion. Clin Ter 2003; 154: 299-303.
17. Kalayci D, Gürgey A, Güven D, et al. Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion. Acta Ophthalmol Scand 1999; 77: 622-624.
18. Linna T, Ylikorkala A, Kontula K, et al. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997; 77: 214-216.
19. Kuhli C, Hattenbach LO, Scharrer I, et al. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 163-168.
20. Larsson J, Sellman A, Bauer B. Activated protein C resistance in patients with central retinal vein occlusion. Br J Ophthalmol 1997; 81: 832-834.
21. Aras S, Yilmaz G, Alpas I, et al. Retinal vein occlusion and factor V Leiden and prothrombin 20210 G:A mutations. Eur J Ophthalmol 2001; 11: 351-355.
22. Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol 2002; 70: 126-132.
23. Marcucci R, Giusti B, Betti I, et al. Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. Thromb Res 2003; 110: 7-12.
24. Gori AM, Marcucci R, Fatini C, et al. Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thromb Haemost 2004; 92: 54-60.
25. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-634.
26. Ihaka R, Gentleman RR. A language for data analysis and graphics. J Comp Graph Stat 1996; 5: 299-314.
27. Bertina RM, Koelemann BPC, Koster T, et al. Mutation in blood coagulations factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
28. Segers K, Dahlbäck B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost 2007; 98: 530-542.
29. Dahlbäck B, Carlsson M, Svensson PJ. Familiar thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: predilection of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
30. Trossaert M, Conard J, Horellou MH, et al. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost 1996; 75: 521-522.
31. Svensson PJ, Zoller B, Dahlback B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 332-335.